SCHEMBL8318326

SCHEMBL8318326

NC[C@H]1CCCN1C(=O)c1cc2ncnc(N[C@@H](CO)c3nc4cc(Cl)ccc4[nH]3)c2cc1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.35
RPS6KB1 P23443 1/20 0.35
AURKB Q96GD4 1/20 0.35
INCENP Q9NQS7 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
PREP P48147 1/20 0.33
CNR1 P21554 6/20 0.33
EGFR P00533 1/20 0.33
AURKA O14965 1/20 0.33
CNR2 P34972 4/20 0.32
HRH4 Q9H3N8 1/20 0.32
SOS1 Q07889 1/20 0.32
FABP4 P15090 1/20 0.32
HSD11B1 P28845 1/20 0.32
HCRTR2 O43614 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2995876 1.00 AKT1 (0.35) AKT1RPS6KB1AURKBINCENPKDM4E
SCHEMBL13772467 0.92 AKT1 (0.35) AKT1RPS6KB1AURKBINCENPKDM4E
SCHEMBL3000755 0.92 CNR1 (0.35) AKT1RPS6KB1AURKBINCENPKDM4E
SCHEMBL4156704 0.91 SOS1 (0.37) KDM4EALDH1A1LMNAHSD17B10HRH3
SCHEMBL3004192 0.91 SOS1 (0.37) KDM4EALDH1A1LMNAHSD17B10HRH3
SCHEMBL3000818 0.91 SOS1 (0.37) KDM4EALDH1A1LMNAHSD17B10HRH3
SCHEMBL2989823 0.91 ALDH1A1 (0.41) ALDH1A1LMNA
SCHEMBL2989821 0.91 ALDH1A1 (0.41) ALDH1A1LMNA
SCHEMBL2994836 0.90 ALDH1A1 (0.33) AKT1RPS6KB1AURKBINCENPKDM4E
SCHEMBL2994832 0.90 ALDH1A1 (0.33) AKT1RPS6KB1AURKBINCENPKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-07-16 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 AKT1 3073/4885RPS6KB1 1257/4885AURKB 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.